WillItSurvive
Pharma and healthcare groups · India

Aurobindo Pharma

aurobindo.com ↗

Indian generics maker producing APIs and finished drugs for US, EU, and global markets.

Protection under test
Assessed 26 July 2026 · Evidence as of 26 July 2026
Something worth protecting exists and is being tested right now.
On the recordSince 26 July 2026 · Checkable from August 2028 · Every call on the record Checkpoint: US tariff phase-in on generics jumps from 0% to 100% after this window closes
The call

Aurobindo's plants and filings keep new rivals out, but existing generics makers and a 2028 US tariff cliff are already pressing on its margins.

Aurobindo makes copies of brand-name drugs (generics) for hospitals and pharmacies around the world. The company is hard to replace because it owns 31 approved factories and has spent decades filing paperwork with regulators, but it faces two big problems: about half its sales come from the US, which may impose massive import taxes starting in 2028, and its factories have failed multiple government safety inspections in the past year, suggesting a deeper problem than one-time mistakes. The key question is whether the company can fix its inspection failures and move enough production to the US to escape the tariff hit.

Why
01
AI pressure: None apparent. AI speeds up dossier writing and QC analytics but cannot replace FDA-approved plants or filed ANDAs. Could AI do the core job? Unlikely.
02
Bigger players: Sun Pharma, Cipla, Dr. Reddy's, Teva, Viatris, Sandoz. Q1 FY26 API sales fell 16% and US formulations dipped, showing commodity pricing pressure from rival generics makers now. Could a giant copy it? No, they are blocked.
03
What protects it. 31 FDA/EMA/MHRA-approved plants and thousands of ANDA/DMF filings that took decades to build, plus vertical API-to-formulation integration.
What would change this call
FDA inspection outcomes at Eugia, Unit III, and Unit VII over the next 2-4 quarters. Whether recent OAIs and warning letters escalate into import alerts or plant shutdowns.
Lannett Indiana capacity ramp and US volume absorption through 2027. Whether tariff-mitigation capacity is real or falls short before the Aug 2028 tariff phase-in.
US formulations and API revenue trend in FY27 quarterly results. Whether the Q1 FY26 declines (US -1.9%, API -16%) were one-off or a sustained margin erosion pattern.
Key numbers
  • FY26 revenue ~$3.9B (₹33,653 crore), up 6% YoY (2026-03-31)
  • Q1 FY26 API sales dropped 16% YoY (2025-06-30)
  • Lannett acquisition closed for $250 million (2026-06-29)
Named risks
  • US tariff escalation to 100% then 200% on generics starting August 2028 against ~46% US revenue exposure. Severity: high
  • Recurring FDA compliance failures: two Eugia OAIs (May-June 2026), Cohance warning letter (Jan 2026), Unit VII Form 483 (Feb 2026). Severity: high
  • Lannett integration and FTC mandated divestiture execution risk over next two quarters after June 29, 2026 close. Severity: medium
  • Commodity price erosion from peer competition, evidenced by Q1 FY26 API sales down 16% YoY. Severity: medium
  • TheraNym CDMO revenue not expected until 2028, leaving near term growth reliant on mature generics business. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Sun PharmacontestingBoth face similar tariff exposure per July 22, 2026 coverage; Sun Pharma has 552 approved ANDAs per third party data
Dr. Reddy's LaboratoriescontestingShares commodity generics price competition and US tariff exposure flagged July 21, 2026
CiplacontestingNamed alongside Aurobindo in tariff impact coverage as similarly exposed Indian peer, July 2026
Teva, Viatris, SandozcontestingNamed as major global US generics players alongside Aurobindo in market research, May 2025
Questions people ask
Is Aurobindo Pharma profitable in 2026?
Yes. Aurobindo reported FY26 consolidated revenue of about Rs 33,653 crore (roughly $3.9B), up around 6% YoY, with a Q4 FY26 EBITDA margin of about 20.4% as of March 31, 2026. However, Q1 FY26 net profit fell 10.2% YoY to Rs 824.2 crore due to weak US formulations and API sales.
Who owns Aurobindo Pharma?
Aurobindo Pharma is publicly traded on NSE and BSE, but the founding Reddy family, P.V. Ramprasad Reddy and K. Nityananda Reddy, retains majority control, holding about 51.8 to 51.9% of shares as of July 24, 2026. Market cap was roughly Rs 88,000 to 89,000 crore (about $10 to 11B) at that date.
Could AI replace Aurobindo Pharma's business?
No. Aurobindo's moat is physical: 31 FDA, EMA and MHRA approved manufacturing plants, thousands of ANDA and DMF filings, and decades of US wholesale distribution relationships. AI is used as a productivity tool for dossier drafting and QC analytics as of 2026, but cannot substitute for regulatory approved manufacturing or liability bearing compliance history.
Is Aurobindo Pharma's biggest risk the US tariff plan or FDA issues?
Both are live threats as of mid 2026. Trump's July 22, 2026 plan sets zero tariffs on generics until August 2028, then 100%, then 200%, hitting Aurobindo's 43 to 49% US revenue exposure. Separately, Eugia subsidiary plants got two FDA Official Action Indicated classifications in May and June 2026.
Who are Aurobindo Pharma's biggest competitors?
Aurobindo competes directly with Sun Pharma, Cipla, Dr. Reddy's Laboratories, Lupin, Zydus Lifesciences, Glenmark, and Gland Pharma among Indian peers, plus global generics giants Teva, Viatris, and Sandoz. All face similar US tariff exposure flagged in coverage as of July 21-23, 2026.
Did Aurobindo Pharma just make a big acquisition?
Yes. Aurobindo completed its $250 million acquisition of Pennsylvania based Lannett Company on June 29, 2026, adding about 4 billion doses of Indiana manufacturing capacity and 113 ANDAs. The FTC required divestiture of four generic products to Quagen Pharmaceuticals to clear the deal in June 2026.
Timeline
  • 2026-07-24Market cap about Rs 88,000-89,000 crore ($10-11bn); Reddy family holds ~51.8-51.9% stake
  • 2026-07-22Trump announces phased US generics tariff: 0% until Aug 2028, then 100%, then 200%
  • 2026-06-29Aurobindo closes $250 million acquisition of Lannett Company
  • 2026-06-18FTC requires divestiture of four generic products to clear Lannett deal
  • 2026-06-04TheraNym Biologics CDMO facility inaugurated in Telangana
  • 2026-06Eugia Unit III facility receives second FDA OAI classification
  • 2026-05-22FY26 results: revenue Rs 33,653 crore, up ~6% YoY, EBITDA margin ~20.4%
  • 2026-05Eugia Kolthur formulation facility classified OAI by US FDA
  • 2026-02Aurobindo Unit VII receives FDA Form 483
  • 2026-01-30Cohance Lifesciences receives FDA warning letter
Revision history
26 July 2026
First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.
In the same band
SolventumNovo NordiskBaxter International
More in Pharma and healthcare groups →
Sources